Eric Frechette
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Eric Frechette has a total of 29 co-authors. Here are the top co-authors by number of shared publications:
- Ciprian Bolca
Surgery Department, Universite de Sherbrooke, Sherbrooke, QC J1K 2R1, Canada
2 shared publications - A. Rashid Dar
Radiation Oncology, Schulich School of Medicine & Dentistry, Western University, London, CAN
1 shared publication - Aaron D. Ward
Western University, Department of Medical Biophysics, 1151 Richmond St, London, Ontario, N6A 3k7, Canada; Western University, Department of Biomedical Engineering, 1151 Richmond St, London, Ontario, N6A 3k7, Canada; Western University, Department of Oncology, 1151 Richmond St, London, Ontario, N6A 3k7, Canada
1 shared publication - Al Gratton
Department of Radiation Oncology, London Health Sciences Centre, London, Canada
1 shared publication - Alexander V. Louie
Department of Radiation Oncology, London Health Sciences Centre, London, Canada
1 shared publication - Andrew Warner
Department of Radiation Oncology, London Health Sciences Centre, London, ON N6A 5W9, Canada
1 shared publication
Latest Publications
- Open Access
- 27 January 2017
- Published by Springer Nature in Radiation Oncology
- Vol. 12 (1) , 30
Short report: interim safety results for a phase II trial measuring the integration of stereotactic ablative radiotherapy (SABR) plus surgery for early stage non-small cell lung cancer (MISSILE-NSCLC)
A phase II trial was launched to evaluate if neoadjuvant stereotactic ablative radiotherapy (SABR) before surgery improves oncologic outcomes in patients with stage I non-small cell lung cancer (NSCLC). We report a mandated interim safety analysis for the first 10 patients who completed protocol treatment. Operable patients with biopsy-proven T1-2 N0 NSCLC were eligible. SABR was delivered using a risk-adapted fractionation (54Gy/3 fractions, 55/5 or 60/8). Surgical resection was planned 10 weeks later at a high-volume center (>200 lung cancer resections annually). Patients were imaged with dynamic positron emission tomography-computed tomography scans using 18F-fludeoxyglucose (18F-FDG-PET CT) and dynamic contrast-enhanced CT before SABR and again before surgery. Toxicity was recorded using CTCAE version 4.0. Twelve patients were enrolled between 09/2014 and 09/2015. Two did not undergo surgery, due to patient or surgeon preference; neither patient has developed toxicity or recurrence. For the 10 patients completing both treatments, median age was 70 (range: 54–76), 60% had T1 disease, and 60% had adenocarcinoma. Median FEV1 was 73% predicted (range: 54–87%). Median time to surgery post-SABR was 10.1 weeks (range: 9.3–15.6 weeks). Surgery consisted of lobectomy (n = 8) or wedge resection (n = 2). Median follow-up post-SABR was 6.3 months. After combined treatment, the rate of acute grade 3–4 toxicity was 10%. There was no post-operative mortality at 90 days. The small sample size included herein precludes any definitive conclusions regarding overall toxicity rates until larger datasets are available. However, these data may inform others who are designing or conducting similar trials. NCT02136355 . Registered 8 May 2014.
- 27 January 2017
- Published by Springer Nature in Radiation Oncology
- Vol. 12 (1) , 30
Open AccessShort report: interim safety results for a phase II trial measuring the integration of stereotactic ablative radiotherapy (SABR) plus surgery for early stage non-small cell lung cancer (MISSILE-NSCLC)
A phase II trial was launched to evaluate if neoadjuvant stereotactic ablative radiotherapy (SABR) before surgery improves oncologic outcomes in patients with stage I non-small cell lung cancer (NSCLC). We report a mandated interim safety analysis for the first 10 patients who completed protocol treatment. Operable patients with biopsy-proven T1-2 N0 NSCLC were eligible. SABR was delivered using a risk-adapted fractionation (54Gy/3 fractions, 55/5 or 60/8). Surgical resection was planned 10 weeks later at a high-volume center (>200 lung cancer resections annually). Patients were imaged with dynamic positron emission tomography-computed tomography scans using 18F-fludeoxyglucose (18F-FDG-PET CT) and dynamic contrast-enhanced CT before SABR and again before surgery. Toxicity was recorded using CTCAE version 4.0. Twelve patients were enrolled between 09/2014 and 09/2015. Two did not undergo surgery, due to patient or surgeon preference; neither patient has developed toxicity or recurrence. For the 10 patients completing both treatments, median age was 70 (range: 54–76), 60% had T1 disease, and 60% had adenocarcinoma. Median FEV1 was 73% predicted (range: 54–87%). Median time to surgery post-SABR was 10.1 weeks (range: 9.3–15.6 weeks). Surgery consisted of lobectomy (n = 8) or wedge resection (n = 2). Median follow-up post-SABR was 6.3 months. After combined treatment, the rate of acute grade 3–4 toxicity was 10%. There was no post-operative mortality at 90 days. The small sample size included herein precludes any definitive conclusions regarding overall toxicity rates until larger datasets are available. However, these data may inform others who are designing or conducting similar trials. NCT02136355 . Registered 8 May 2014.
- Open Access
- 8 June 2016
- Published by Wiley in Canadian Respiratory Journal
- Vol. 2016, 1-6
Identifying Primary Spontaneous Pneumothorax from Administrative Databases: A Validation Study
Introduction. Primary spontaneous pneumothorax (PSP) is a disorder commonly encountered in healthy young individuals. There is no differentiation between PSP and secondary pneumothorax (SP) in the current version of the International Classification of Diseases (ICD-10). This complicates the conduct of epidemiological studies on the subject.Objective. To validate the accuracy of an algorithm that identifies cases of PSP from administrative databases.Methods. The charts of 150 patients who consulted the emergency room (ER) with a recorded main diagnosis of pneumothorax were reviewed to define the type of pneumothorax that occurred. The corresponding hospital administrative data collected during previous hospitalizations and ER visits were processed through the proposed algorithm. The results were compared over two different age groups.Results. There were 144 cases of pneumothorax correctly coded (96%). The results obtained from the PSP algorithm demonstrated a significantly higher sensitivity (97% versus 81%,) and positive predictive value (87% versus 46%,) in patients under 40 years of age than in older patients.Conclusions. The proposed algorithm is adequate to identify cases of PSP from administrative databases in the age group classically associated with the disease. This makes possible its utilization in large population-based studies.- 8 June 2016
- Published by Wiley in Canadian Respiratory Journal
- Vol. 2016, 1-6
Open AccessIdentifying Primary Spontaneous Pneumothorax from Administrative Databases: A Validation Study
Introduction. Primary spontaneous pneumothorax (PSP) is a disorder commonly encountered in healthy young individuals. There is no differentiation between PSP and secondary pneumothorax (SP) in the current version of the International Classification of Diseases (ICD-10). This complicates the conduct of epidemiological studies on the subject.Objective. To validate the accuracy of an algorithm that identifies cases of PSP from administrative databases.Methods. The charts of 150 patients who consulted the emergency room (ER) with a recorded main diagnosis of pneumothorax were reviewed to define the type of pneumothorax that occurred. The corresponding hospital administrative data collected during previous hospitalizations and ER visits were processed through the proposed algorithm. The results were compared over two different age groups.Results. There were 144 cases of pneumothorax correctly coded (96%). The results obtained from the PSP algorithm demonstrated a significantly higher sensitivity (97% versus 81%,) and positive predictive value (87% versus 46%,) in patients under 40 years of age than in older patients.Conclusions. The proposed algorithm is adequate to identify cases of PSP from administrative databases in the age group classically associated with the disease. This makes possible its utilization in large population-based studies. - 1 October 2014
- Published by Elsevier in The Annals of Thoracic Surgery
- Vol. 98 (4) , 1496-1498
Repair of Complete Longitudinal Esophageal Rupture With Preservation of Esophageal Motility
- 1 October 2014
- Published by Elsevier in The Annals of Thoracic Surgery
- Vol. 98 (4) , 1496-1498
Repair of Complete Longitudinal Esophageal Rupture With Preservation of Esophageal Motility
- 4 March 2011
- Vol. 59 (4) , 201-3
[Video-assisted thoracoscopic lobectomy--the treatment of choice for stage I NSCLC].
Video-assisted thoracic surgery (VATS) in the diagnosis and treatment of stage I NSCLC has been used since the early 1990s. This report aims to provide a retrospective analysis of the literature in order to present the advantages of VATS lobectomy compared with open resection. The best available evidence strongly suggests that VATS lobectomy is less morbid than open lobectomy, the postoperative quality of life is superior and long-term oncologic results are equivalent. All these data supports the idea that VATS lobectomy is the treatment of choice for stage I NSCLC.
- 4 March 2011
- Vol. 59 (4) , 201-3
[Video-assisted thoracoscopic lobectomy--the treatment of choice for stage I NSCLC].
Video-assisted thoracic surgery (VATS) in the diagnosis and treatment of stage I NSCLC has been used since the early 1990s. This report aims to provide a retrospective analysis of the literature in order to present the advantages of VATS lobectomy compared with open resection. The best available evidence strongly suggests that VATS lobectomy is less morbid than open lobectomy, the postoperative quality of life is superior and long-term oncologic results are equivalent. All these data supports the idea that VATS lobectomy is the treatment of choice for stage I NSCLC.